Previous close | 11.82 |
Open | 11.79 |
Bid | 11.80 x 200 |
Ask | 12.05 x 200 |
Day's range | 11.68 - 12.02 |
52-week range | 4.20 - 15.12 |
Volume | |
Avg. volume | 149,796 |
Market cap | 302.281M |
Beta (5Y monthly) | 0.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.96 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 28.79 |
BOSTON, March 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced new results from the first-ever global LGSOC Patient Impact Survey, developed with patient advocates and community medical leaders to better understand and address the complex needs and experiences of those living with low-grade serous ovarian cancer (LGSOC). The results reveal a significant negative impact of LGSOC on respondents’ m
BOSTON, March 14, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2023, and highlighted recent progress.
BOSTON, March 11, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced multiple oral and poster presentations, including a late-breaking oral presentation of avutometinib and defactinib combination from the RAMP 201 Part A trial in heavily pretreated patients with low-grade serous ovarian cancer (LGSOC), at the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, to be held on Ma